Galderma Group
ISIN CH1335392721
|WKN A407X6
Overview
Description
Galderma Group AG engages in the provision of science-based premium dermatology solutions. The firm is also involved in delivering a synergistic portfolio of flagship brands spanning the full spectrum of the fast-growing self-care dermatology market. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Switzerland
Financials
Key metrics
| Market capitalisation, EUR | 20,078.63 m |
| EPS, EUR | - |
| P/B ratio | 2.64 |
| P/E ratio | 91.71 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 4,080.00 m |
| Net income, EUR | 213.71 m |
| Profit margin | 5.24% |
What ETF is Galderma Group in?
There are 184 ETFs which contain Galderma Group. All of these ETFs are listed in the table below. The ETF with the largest weighting of Galderma Group is the UBS ETF (CH) SMIM (CHF) A-dis.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
